FBRX — Forte Biosciences, Inc.

Summary of Forte Biosciences Q1 2021 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Forte ended Q1 2021 with approximately $54.8 million in cash and cash equivalents, sufficient to fund operations for at least the next 12 months.
• Cash Utilization: The company reported cash utilization of $4.0 million for the quarter.
• Expenses:
  • Research and Development (R&D) expenses were $3.3 million, up from $1.4 million in Q1 2020, primarily due to manufacturing and clinical development costs.
  • General and Administrative (G&A) expenses increased to $1.4 million from $0.7 million in the prior year, attributed to professional fees and increased headcount.
• Loss per Share: Reported losses per share were $0.36, an improvement from $0.97 in Q1 2020.

2. Strategic Updates and Business Highlights

• Forte is advancing its lead product candidate, FB-401, a live biotherapeutic for the treatment of atopic dermatitis, particularly in pediatric patients.
• The FDA granted Fast Track designation for FB-401, highlighting the unmet need in treating atopic dermatitis.
• Enrollment for the phase 2 randomized controlled study exceeded expectations, with 154 subjects enrolled (target was 124).
• Positive results from a previous phase 2a study showed significant improvement in atopic dermatitis symptoms, with a 90% EASI-50 response rate in treated pediatric patients.
• The company has expanded its patent portfolio to 11 U.S. patents and is pursuing additional filings internationally.

3. Forward Guidance and Outlook

• Forte anticipates an increase in R&D expenses over the next year as it continues clinical development for FB-401.
• The company expects to announce results from the ongoing phase 2 trial in the third quarter of 2021.
• There is a focus on developing a global strategy for regulatory submissions, including potential filings in Europe and Asia.

4. Bad News, Challenges, or Points of Concern

• The company faces challenges related to the regulatory landscape, particularly concerning the oversight of live biotherapeutics by the FDA's division of vaccines and related products.
• There is inherent risk in clinical trials, including the need for a clean safety profile and achieving clinically meaningful efficacy metrics to ensure market acceptance.
• Competitive pressures exist in the dermatological space, particularly for therapies targeting pediatric populations.

5. Notable Q&A Insights

• Endpoints Discussion: The company clarified the use of EASI-50 as a primary endpoint for phase 2 trials, with plans to use IGA in phase 3 studies.
• Open Label Extension: An open label extension for the phase 2 study will include placebo patients, focusing on safety over a year-long period.
• Age Stratification: Approximately 75% of trial participants are under 18, with compliance expected to be manageable due to the nature of the therapy.
• Device and Human Factors: The spray device used for FB-401 is already in use in an approved product, minimizing anticipated issues. Human factor studies are underway.
• Regulatory Pathway: The company is preparing for potential regulatory discussions in Europe and Asia, with a focus on using EASI scores for submissions.

Overall, Forte Biosciences is positioned to make significant strides in the treatment of atopic dermatitis, with a strong cash position and promising clinical data, while navigating regulatory complexities and market competition.